CONFIDENTIAL TREATMENT REQUESTED FOR PORTIONS OF THIS EXHIBIT AMENDMENT NO. 1 TO D-LUCIFERIN SUPPLY AGREEMENTD-Luciferin Supply Agreement • August 15th, 2005 • Xenogen Corp • Measuring & controlling devices, nec
Xenogen Corporation, with a principal place of business at 860 Atlantic Avenue, Alameda, CA 94501 (“Xenogen”) and Biosynth International, Inc., with a principal place of business at 1665 West Quincy Avenue, Suite 155, Naperville, IL 60540 (“Biosynth”), (each a “Party” and collectively, the “Parties”), hereby amend that certain D-Luciferin Supply Agreement, dated December 31, 2001, by and between the Parties hereto (the “Agreement”), effective as of April , 2004 (the “Amendment Date”).
CONFIDENTIAL TREATMENT REQUESTED. PORTIONS OF THIS AGREEMENT HAVE BEEN REDACTED AND FILED SEPARATELY WITH THE COMMISSION.] D-LUCIFERIN SUPPLY AGREEMENTD-Luciferin Supply Agreement • May 10th, 2004 • Xenogen Corp • Services-commercial physical & biological research • California
This D-Luciferin Supply Agreement (the “Agreement”), effective as of December 31, 2001 (the “Effective Date”), is made by and between Biosynth International, Inc., an Illinois corporation, having a place of business at 1665 West Quincy Avenue, Suite 155, Naperville, IL 60540 (“Biosynth”), and Xenogen Corporation, a California corporation, having a place of business at 860 Atlantic Avenue, Alameda, CA 94501 (“Xenogen”) (each a “Party,” collectively “Parties”).
